文献速递神经肿瘤

少突胶质细胞瘤管理趋势:一项多国多学科调查研究

Trends in the Management of Oligodendrogliomas: A Multinational and Multidisciplinary Survey Study.
PubMed 文献 · World Neurosurg · 2025-03-11

该研究于2023年2月至7月向4个神经外科/神经肿瘤学会发放20题问卷,调查少突胶质细胞瘤的诊疗实践。共63名医生回复,来自12个国家。诊断实践一致,但治疗推荐存在差异,尤其在替莫唑胺单药化疗、次全切除后处理及3级辅助治疗方面,且差异与地区相关。

要点

  • 63名来自12个国家的医生回复,诊断实践一致但治疗推荐存在差异。
  • 新诊断少突胶质细胞瘤中,很少、有时、经常单用替莫唑胺者分别占36.5%、25.4%、30.2%。
  • 2级次全切除后,33.3%推荐 upfront 放化疗,27.0%推荐观察,39.7%选择其他方案。

核心结论

  • 研究强调少突胶质细胞瘤管理的复杂性及持续研究以优化治疗策略的重要性。
  • 原文结论指出,尤其随着异柠檬酸脱氢酶抑制剂进入实践,需进一步研究以追踪实践模式并重新评估推荐。

研究设计与样本

  • 研究为一项20题问卷调查,于2023年2月至7月分发给4个神经外科/神经肿瘤学会。
  • 调查收集人口学、诊断实践和治疗决策数据,采用卡方/Fisher精确检验分析。
  • 共63名医生回复,代表12个国家。

主要发现

  • 诊断实践在回复者中一致,但治疗推荐存在差异。
  • 新诊断少突胶质细胞瘤患者中,很少、有时、经常单用替莫唑胺作为唯一化疗的提供者分别占36.5%、25.4%、30.2%。
  • 2级少突胶质细胞瘤次全切除后,33.3%的提供者推荐 upfront 放疗/化疗,27.0%推荐观察,其余39.7%分散于手术、化疗和临床试验等选项。
  • 欧洲提供者更常推荐手术(33.3% vs. 0.0%),而美国/加拿大提供者更常推荐放疗/化疗(35.7% vs. 26.7%)或观察(31.0% vs. 13.3%)(P = 0.009)。
  • 3级少突胶质细胞瘤辅助治疗中,47.6%推荐放疗/丙卡巴肼、洛莫司汀和长春新碱,33.3%推荐放疗/替莫唑胺;欧洲提供者更常推荐放疗/丙卡巴肼、洛莫司汀和长春新碱(86.7% vs. 33.3%),美国/加拿大提供者更常推荐放疗/替莫唑胺(40.5% vs. 6.7%;P = 0.004)。

关键数值与推荐

  • 很少、有时、经常单用替莫唑胺作为唯一化疗的比例分别为36.5%、25.4%、30.2%。
  • 2级次全切除后,推荐 upfront 放疗/化疗33.3%,观察27.0%,其他选项合计39.7%。
  • 3级辅助治疗中,推荐放疗/丙卡巴肼、洛莫司汀和长春新碱47.6%,推荐放疗/替莫唑胺33.3%。
  • 地区差异:欧洲 vs. 美国/加拿大推荐手术33.3% vs. 0.0%,放疗/化疗35.7% vs. 26.7%,观察31.0% vs. 13.3%(P = 0.009);放疗/丙卡巴肼、洛莫司汀和长春新碱86.7% vs. 33.3%,放疗/替莫唑胺40.5% vs. 6.7%(P = 0.004)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Oligodendrogliomas present challenges in management despite their favorable prognosis. Optimal therapeutic strategies are not well-established. We aimed to characterize current practice patterns and identify areas of discordance in oligodendroglioma management. METHODS: A 20-question survey was distributed February-July 2023 to 4 professional neurosurgery/neuro-oncology societies to assess practices in oligodendroglioma management. The survey collected data on demographics, diagnostic practices, and treatment decisions. Data analysis was performed using chi-square/Fisher's exact tests. RESULTS: Sixty-three physicians responded, representing 12 countries. Diagnostic practices were consistent among respondents. However, variations in management recommendations were observed. Providers were divided between rarely (36.5%), sometimes (25.4%), and often (30.2%) using temozolomide (TMZ) as sole chemotherapy for patients with newly diagnosed oligodendroglioma. For patients with subtotal resection of grade 2 oligodendroglioma, 33.3% of providers recommended upfront radiation/chemotherapy, 27.0% recommended observation, and the remaining 39.7% were divided among options including surgery, chemotherapy, and clinical trials. European providers more frequently recommended surgery (33.3% vs. 0.0%), whereas radiation/chemotherapy (35.7% vs. 26.7%) or observation (31.0% vs. 13.3%) was more commonly recommended by U.S./Canada providers (P = 0.009). Providers also disagreed on adjuvant therapy for grade 3 oligodendroglioma. 47.6% recommended radiation/procarbazine, lomustine, and vincristine, and 33.3% recommended radiation/TMZ. This decision varied by region, with European providers more frequently recommending radiation/procarbazine, lomustine, and vincristine (86.7% vs. 33.3%) and U.S./Canadian providers more frequently recommending radiation/TMZ (40.5% vs. 6.7%; P = 0.004). CONCLUSIONS: This study underscores the complexity of oligodendroglioma management and the importance of ongoing research to refine therapeutic strategies. Further studies, especially with the introduction of isocitrate dehydrogenase inhibitors in practice, are warranted to track practice patterns and reassess recommendations.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Jiang K, Kalluri A, Odonkor M, et al. Trends in the Management of Oligodendrogliomas: A Multinational and Multidisciplinary Survey Study. World Neurosurg. 2025. PMID: 39947316. doi:10.1016/j.wneu.2025.123716

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。